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Purpose: To evaluate the atherosclerotic evolution in coronary bifurcations located proximally and distally to a
bioresorbable scaffold.
Methods: Thirty bifurcations located >5 mm beyond the scaffolded segment, being investigated with serial
intravascular ultrasound virtual histology (IVUS-VH) examinations, at baseline and 2-years, in patients enrolled in the
ABSORB cohort B1 study were included in this analysis. In each bifurcation, the frames portraying the proximal rim,
in-bifurcation, and distal rim of the ostium of the side branch were analyzed. The geometric parameters and plaque
types were evaluated at baseline and 2-years follow-up.
Results: There were no significant differences in the geometrical parameters such as lumen, vessel and plaque areas as
well as in the composition of the atheroma between baseline and 2-years follow-up.
When we separately examined the bifurcations located proximally and distally to the scaffolded segment, no changes
were found at the distal bifurcations, while at the proximal bifurcations there was a statistical significant decrease in the
plaque burden (36.67 ± 13.33% at baseline vs. 35.06 ± 13.20% at 2 years follow-up, p = 0.04).
Ten necrotic core rich plaques were found at baseline, of which 2 regressed to either fibrotic plaque or to intimal
thickening at 2 years follow-up. The other 8 did not change. Disease progression was noted in 3 plaques (1 adaptive
intimal thickening, 1 fibrotic and 1 fibrocalcific plaque) that evolved to necrotic rich plaques.
Conclusions: Plaque regression was noted at the bifurcations located proximally to the bioresorbable scaffold but not
at these located distally. Additional studies are required to confirm this finding and examine further the effect of drug
elution on atherosclerotic evolution.
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Although atherosclerosis is a systemic disease it has
focal and eccentric manifestations. This paradox has
been attributed to local triggers such as the blood flow
hemodynamics [1,2]. Coronary bifurcations are prone to
atherosclerosis as in these segments complex flow pat-
tern are noted that can induce plaque development.
Hence, lesions in coronary bifurcations are a common
finding and in SYNTAX study 63% of the randomized
patients had obstructive disease in these anatomies [3].
Coronary angiography has limited capability in assessing
atherosclerotic disease progression/regression in bifur-
cation lesions as in these segments there is an overlap-
ping of branches and the increased density of the
contrast agent does not permit accurate quantification
of vessel dimensions [4,5]. In addition, coronary angiog-
raphy cannot provide any information regarding the
plaque burden and quantify changes in its composition.
These drawbacks were addressed by intravascular
ultrasound (IVUS) imaging which allows accurate quan-
tification of the lumen and vessel wall dimensions and
permits accurate assessment of atheroma burden [6].
The ability of gray-scale IVUS to characterize the com-
position of the coronary plaque appears to be moderate,
a limitation that was overcome with the development of
IVUS virtual histology (VH) that is able to provide ac-
curate detection and quantification of different plaque
types [7,8]. These unique qualities have rendered IVUS/
IVUS-VH a useful tool in the study of atherosclerosis.
Therefore many IVUS based trials have been conducted
or are underway that examine the natural evolution of
atherosclerosis and the effects of different invasive and
non-invasive treatments on plaque progression [9-13].
With regards to coronary bifurcations there is only one
report which used serial IVUS and optical coherence tom-
ography (OCT) examinations to evaluate plaque progres-
sion [14]. In this report there was no difference in luminal
dimensions, plaque composition and its burden between
baseline and at 6 months follow-up. The reported results
might be due to the short time interval between the 2
examinations. The aim of this study is to provide further
information about the plaque evolution in coronary bifur-
cations. In contrast to the previous study the time interval
between the baseline and follow-up examination is longer
(2 years) and we analyze separately bifurcations located
proximally and distally to an implanted drug eluting scaf-
fold in order to detect a potential effect of the downstream
drug delivery on atherosclerotic evolution.
Methods
Study population
We analyzed data from patients with obstructive coronary
artery diseases who underwent percutaneous coronary
intervention with the everolimus-eluting bioresorbablevascular scaffold (BVS; ABSORB®, Abbott Vascular, Santa
Clara, CA, USA). Out 45 included patients that were en-
rolled in the ABSORB cohort B1 study and had invasive
assessment including IVUS and IVUS-VH examinations at
baseline and at 2 years follow-up [15], 12 patients
portrayed bifurcations located >5mm away from the scaf-
fold (19 proximally and 11 distally) segment and had side
branch orifice measured by IVUS >1.5mm (Figure 1). The
sponsor of this study was Abbott Vascular.
IVUS-VH acquisition
IVUS examination was performed by a phased-array,
20MHz, 3.2F IVUS catheter (Eagle Eye, Volcano Corpor-
ation, Rancho Cordova, California) using an automatic
continuous pull-back device operating at a speed of 0.5
mm/s. The IVUS grayscale and IVUS-VH analyses were
performed offline using the pcVH 2.1 software (Volcano
Corporation, Rancho Cordova, California).
Bifurcation analysis
Only the pullback in the main branch was available for
the current analysis. The analyzed bifurcation lesions
were classified into the proximal or distal bifurcation
group based on its location. The proximal bifurcation
group included bifurcations located proximally to the
scaffolded segment and the distal group these located
distally. In each bifurcation the cross-sectional frames
that portrayed 1) the proximal rim of the ostium of the
side branch, 2) the bifurcation cross-section and 3) the
distal rim of the ostium of the side branch, were identi-
fied and included in the final analysis. The proximal rim
of the ostium of the side branch was portrayed by the
first frame proximally to the take off of the side branch;
the bifurcation cross-section corresponded to the frame
with the largest ostial diameter of the side branch while
the distal rim of the ostium of the side branch by the
first frame located distally to the side branch (Figure 2).
In each IVUS frame the lumen area, vessel area and
plaque area were measured while the plaque burden was
computed by the equation: plaque burden = 100 x plaque
area/vessel area [6].
Plaque type classification
IVUS-VH allowed identification of four plaque types:
dense calcium (DC), necrotic core (NC), fibrofatty (FF)
and fibrotic tissue (FT) that are illustrated in a color
coded map, with the white color corresponding to the
calcified tissue, the red to the necrotic core, the light
green to the fibrofatty and the green to fibrotic tissue.
Based on the type of the plaque detected by IVUS-VH, 2
experienced observers classify the atheromas in 2 groups:
1) those with high percentages of fibrotic tissue without a
significant amount of NC (adaptive intimal thickening,
pathological intimal thickening, fibrocalcific plaque, and
Figure 1 Selection of the bifurcations included in the current analysis. Only the bifurcations located >5mm proximally and distally to the
implanted scaffold were studied. Plaques were analyzed only in the main coronary artery at the proximal rim of the ostium of the side branch, at
the in-bifurcation site and at the distal rim of the ostium of the side branch.
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burden (>40%) and more than 10% NC component
(fibroatheroma and calcified fibroatheroma). In case that
the NC was in direct contact with the lumen the atheroma
was classified as thin cap fibroatheroma (TCFA) or calcified
thin cap fibroatheroma when the Ca burden was >10%
[16,17].
These plaque types were reported per location within
the bifurcation (i.e., cross-section at the proximal rim of
the ostium of the side branch, at the bifurcation point
and at the distal rim of the ostium of the side branch)
and per bifurcation using a hierarchical approach that
classified the atheroma based on the worst plaque type
detected within the 3 studied frames [18]. To evaluate
changes in the composition of the plaque which mayFigure 2 A typical example of an analyzed bifurcation segment
at baseline and at 2 years follow-up. Panel A portrays the
proximal rim of the ostium of the side branch, B the in-bifurcation
segment and C the distal rim of the ostium of the side branch.have a potential impact on prognosis, we estimated an
IVUS-VH-derived plaque risk index in each bifurcation.
This indice has already been described in the previous
literature [14], and is given as the ratio of the sum of the
NC-rich plaques vs. the sum of non-NC-rich plaques.
Statistical analysis
Categorical variables are presented as frequencies and
percentages. Continuous variables are presented as
means ± standard deviations. For 2-related sample com-
parison of continuous variables the Wilcoxon test was
used. A p value <0.05 was considered statistically signifi-
cant. The bifurcation (lesion) was the unit of analysis
without corrections for correlated observations in the
same subjects. Statistical analyses were performed using
SPSS version 18.0 for Windows (SPSS, Inc., Chicago, IL,
USA).
Results
Baseline characteristics
The median age of the studied population was 65.52 ±
8.01 years; 60% of the patients had stable angina and all
of them were treated with statins during the follow-up.
None of these patients had sustained a cardiovascular
event due to disease progression in the studied bifur-
cation. The clinical characteristics of the 12 patients (30
bifurcations, 19 located proximally and 11 distally to the
BVS) included in the analysis are illustrated in Table 1.
Geometrical and compositional analysis of the IVUS
derived measurements
Table 2 provides the results from the geometrical and
compositional analysis at the proximal rim of the ostium
of the side branch, in-bifurcation, and distal rim of the
Table 1 Baseline clinical and angiographic characteristics
of the studied population (n = 12)
Patients characteristics Number of patients
Age 65.52 ± 8.01
Men 9 (75%)
Hypertension 4 (33%)
Hypercholesterolemia 11 (92%)
Diabetes 0 (0%)
Smoking 0 (0%)
Previous MI 4 (33%)
Previous PCI 2 (17%)
Clinical presentation
Stable angina 10 (83%)
Unstable angina 1 (8%)
Silent ischemia 0 (0%)
Treated vessel
LAD 7 (58%)
LCX 3 (25%)
RCA 2 (17%)
Medications
Beta-blockers 6 (50%)
ACE inhibitors/ARBs 5 (41%)
Statins 12 (100%)
Calcium-channel blocker 3 (25%)
Table footnote: ACE angiotensin-converting enzyme, ARB angiotensin receptor
blocker, PCI percutaneous coronary artery, LAD left anterior descending
coronary artery, LCX left circumflex coronary artery, RCA right coronary artery.
Table 2 Luminal vessel wall and plaque measurements
and compositional data in each region of the bifurcation
at baseline and at 2 years follow-up (n = 30 bifurcations)
Variable Baseline 2 years follow-up p value
Vessel CSA (mm2)
Distal 12.94 ± 4.35 13.22 ± 4.36 0.27
In-bifurcation 14.96 ± 5.65 15.11 ± 5.78 0.33
Proximal 15.22 ± 5.99 15.23 ± 5.89 0.80
Lumen CSA (mm2)
Distal 7.89 ± 3.16 8.16 ± 2.80 0.20
In-bifurcation 10.02 ± 4.35 10.25 ± 4.40 0.28
Proximal 9.05 ± 4.06 9.34 ± 4.25 0.25
Plaque CSA (mm2)
Distal 5.05 ± 3.19 5.05 ± 3.36 0.58
In-bifurcation 4.93 ± 2.93 4.90 ± 3.17 0.98
Proximal 6.18 ± 3.48 5.87 ± 3.33 0.12
Plaque burden (%)
Distal 37.54 ± 14.21 36.36 ± 14.20 0.23
In-bifurcation 32.63 ± 12.60 31.74 ± 12.71 0.41
Proximal 39.43 ± 13.70 38.11 ± 14.35 0.25
DC CSA (mm2)
Distal 0.37 ± 0.80 0.33 ± 0.63 0.84
In-bifurcation 0.28 ± 0.55 0.32 ± 0.59 0.25
Proximal 0.30 ± 0.50 0.30 ± 0.51 0.46
DC (%)
Distal 11.86 ± 21.49 9.40 ± 13.28 0.93
In-bifurcation 15.61 ± 22.30 14.04 ± 18.14 0.86
Proximal 10.66 ± 18.39 9.84 ± 15.56 0.87
NC CSA (mm2)
Distal 0.42 ± 0.72 0.49 ± 0.90 0.44
In-bifurcation 0.38 ± 0.58 0.43 ± 0.82 0.48
Proximal 0.51 ± 0.71 0.55 ± 0.79 0.84
NC (%)
Distal 11.00 ± 13.18 12.94 ± 16.25 0.51
In-bifurcation 13.63 ± 11.04 15.66 ± 12.83 0.36
Proximal 13.69 ± 11.17 15.08 ± 13.05 0.31
Fibrofatty CSA (mm2)
Distal 0.19 ± 0.37 0.26 ± 0.76 0.97
In-bifurcation 0.32 ± 0.69 0.28 ± 0.75 0.23
Proximal 0.32 ± 0.52 0.32 ± 0.74 0.53
Fibrofatty tissue (%)
Distal 5.41 ± 8.65 6.32 ± 15.03 0.85
In-bifurcation 8.42 ± 12.82 6.48 ± 11.42 0.39
Proximal 8.68 ± 10.25 9.09 ± 13.95 0.60
Fibrotic CSA (mm2)
Distal 0.94 ± 1.41 0.78 ± 1.25 0.26
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lumen, vessel wall areas and the plaque burden did not
change at 2 years follow-up. No statistical significant dif-
ferences were noted in the composition of the plaque be-
tween baseline and follow-up apart from a decrease in the
fibrotic tissue component at the proximal rim of the ost-
ium of the side branch (1.15mm2 vs. 0.70mm2, p = 0.01).
Distribution of IVUS-VH-derived plaque types at the three
bifurcation regions
The distribution of NC-rich and NC-poor plaques is
presented in Table 3. NC-rich plaques were more fre-
quently located at proximal rim and distal rim than the
in-bifurcation site at baseline and at 2 years follow-up.
The plaque risk index was higher at 2 years follow-up
suggesting increase of the number of NC-rich plaques.
Geometric and compositional comparison of the IVUS
measurements based on the location of the bifurcation
As it would have been expected the vessel and lumen
cross-sectional areas were larger at the proximal bifurca-
tions than at the distal bifurcations at baseline and at 2
years follow-up (p < 0.05). There were no changes in the
Table 2 Luminal vessel wall and plaque measurements
and compositional data in each region of the bifurcation
at baseline and at 2 years follow-up (n = 30 bifurcations)
(Continued)
In-bifurcation 1.05 ± 1.27 0.93 ± 1.32 0.26
Proximal 1.62 ± 1.70 1.21 ± 1.43 0.01
Fibrotic tissue (%)
Distal 28.39 ± 30.79 21.38 ± 24.45 0.13
In-bifurcation 35.44 ± 27.72 37.20 ± 26.75 0.82
Proximal 46.28 ± 28.32 38.33 ± 28.77 0.10
Table footnote: CSA cross sectional area, DC dense calcium, NC necrotic core.
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mm2 vs. 10.67 ± 4.14 mm2, p = 0.09 and 16.37 ± 5.15
mm2 vs. 16.50 ± 5.20 mm2, p = 0.44 respectively) and
distal group (6.62 ± 1.67 mm2 vs. 6.83 ± 1.86 mm2, p =
0.23 and 10.96 ± 3.98 mm2 vs. 11.13 ± 3.88 mm2, p = 0.31,
respectively) between baseline and 2 years follow-up
(Figure 3). On the other hand at follow-up the percent
plaque burden was decreased at the proximal bifurcation
from 36.67 ± 13.33% to 35.06 ± 13.20% (p = 0.04), but did
not change at the distal bifurcation (36.22 ± 14.44% vs.
35.91 ± 15.15%, p = 0.67). There were no changes in the
composition of the plaque in the proximal group (p =
0.633 for the DC p = 0.58 for the NC, p = 0.84 for the
fibrofatty and p = 0.10 for the fibrotic component) while
at the distal group there was only a reduction in the
fibrofatty component at 2 years follow-up (p = 0.73 for
the DC, p = 0.13 for the NC, p = 0.02 for the fibrofatty
and p = 0.53 for the fibrotic tissue) (Figure 4).
Bifurcation plaque type
At baseline, 10 NC-rich plaques were found, 4 of which
were classified as thin-cap lesions (1 TCFA and 3 calci-
fied TCFA) (Figure 5). One fibroatheroma became
pathological intimal thickening and another calcified
fibroatheroma became fibrotic plaque suggesting disease
regression in these plaques. On the other hand 3 newTable 3 Plaque type at distal rim, in- bifurcation, and proxim
2 years follow-up and IVUS-VH derived plaque risk index
Non-NC-rich plaques
Segment AIT PIT FC FT
Distal rim,BL 18 (60) 1 (3.3) 3 (10) 2 (6.7)
Distal rim, 2y 19 (63.3) 0 (0) 3 (10) 1 (3.3)
In- bifurcation, BL 21 (70) 0 (0) 5 (16.7) 1 (3.3)
In- bifurcation, 2y 24 (80) 0 (0) 4 (13.3) 0 (0)
Proximal rim, BL 17 (56.7) 1 (3.3) 3 (10) 3 (10)
Proximal rim, 2y 17 (58.6) 1 (3.4) 2 (6.9) 2 (6.9)
Table footnote: AIT adaptive intimal thickening, BL baseline, CaFA calcified fibroathe
fibrocalcific plaque, FT fibrotic plaque, IVUS intravascular ultrasound, NC necrotic co
virtual histology.
* The plaque risk index is defined as the sum of NC rich vs. non-NC rich plaques.NC-rich lesions developed from 1 adaptive intimal thick-
ening, 1 fibrotic and 1 fibrocalcific plaques implying dis-
ease progression. Eight NC-rich plaques (80%) did not
change at follow-up. Most of the thin-cap lesions (n = 3,
75%) were also unchanged apart from 1 calcified TCFA
that became calcified fibroatheroma.
Discussion
In this analysis we used serial IVUS-VH to examine the
atherosclerotic evolution in coronary bifurcations. We
found no significant changes with respects to the lu-
minal and vessel wall dimensions, and plaque burden as
well as its composition at 2 years follow-up. However,
when we examined separately the bifurcations located
proximally and distally to an implanted BVS, we noted
plaque regression in proximal bifurcation group while
the plaque burden did not change in the distal group.
Although there is sufficient evidence to support the
prognostic implications of the atheroma burden and its
composition, there is limited information about the ath-
erosclerotic evolution [12,19,20]. In a recent report Kubo
et al. used serial IVUS-VH to study changes in the type
of the plaque and the atheroma burden in 99 patients.
Two hundred sixteen non-culprit lesions were evaluated
at baseline and at 12 months follow-up. At follow-up 12
TFCAs developed while most (75%) of the detected
TCFAs (n = 20) at baseline evolved to a more stable
plaque types suggesting disease regression [9]. This
study highlighted the dynamic nature of coronary
atherosclerosis and demonstrated that atherosclerotic
evolution includes not only disease progression but it is
also likely high risk plaque to regress and become more
stable. In a similar study Diletti et al. used serial OCT and
IVUS-VH examinations to assess changes in the atheroma
burden and its composition in coronary bifurcations [14].
Twenty seven NC-rich plaques were detected at baseline
most of which (81%) did not show any significant change
at 6 months follow-up. Although the bifurcation lesions
analyzed in the present study revealed lower plaque riskal rim of the ostium of the side branch at baseline and at
NC-rich plaques
CaFA FA CaTCFA TCFA Plaque risk index*
4 (13.3) 1 (3.3) 1 (3.3) 0 (0) 6/24 = 0.25
6 (20) 0 (0) 1 (3.3) 0 (0) 7/23 = 0.30
2 (6.7) 1 (3.3) 0 (0) 0 (0) 3/27 = 0.11
2 (6.7) 0 (0) 0 (0) 0 (0) 2/28 = 0.07
2 (6.7) 0 (0) 2 (6.7) 1 (3.3) 5/24 = 0.21
4 (13.8) 0 (0) 3 (10.3) 0 (0) 7/22 = 0.32
roma, CaTCFA calcified thin-cap fibroatheroma, FA fibroatheroma, FC
re, PIT pathologic intimal thickening, TCFA thin-cap fibroatheroma, VH
Figure 3 Lumen and vessel wall areas at baseline and at 2 years follow-up at the bifurcations located proximally (A) and distally (B) to
the bioresorbable scaffold (proximal and distal bifurcation group).
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found no differences in the plaque volume and its com-
position but we also reported regional changes of the type
of the plaque as 2-rich NC plaques regressed to more
stable forms and 3 new NC-rich plaques developed at
follow-up. An increase in the plaque risk index was noted
at 2 years suggesting disease progression even under the
standard medication therapy including statins.
It is well known that bifurcation anatomies are prone
to atherosclerosis; and recently we have showed that the
lesions located at the bifurcation site have an increased
atheroma burden and lipid component compared to the
lesions located in a non-bifurcated segment [21]. The
differences in the plaque composition and burden be-
tween bifurcation and non-bifurcation lesions should at
least partially be attributed to the complex flow patterns
seen in these segments. The local hemodynamics seems
to affect not only the plaque burden but also the distri-
bution of the plaque which is unevenly distributed inFigure 4 Plaque composition at the bifurcations located proximally a
bifurcation group) at baseline and at 2 years follow-up. The white colo
green to fibrofatty tissue and the dark green to fibrotic tissue.coronary bifurcations. In a Gonzalo et al. showed that
NC-rich plaques are seen more often in the proximal
rim of the ostium of the side branch than in the distal
rim [16]. We also found an increased lipid component
and plaque burden in the proximal rim of the ostium of
the side branch and in the distal rim of the ostium of
the side branch while less plaque was seen in the in-
bifurcation segment. The increased plaque burden seen
in the proximal rim of the ostium of the side branch
should be probably attributed to the disturbed flow often
seen before the flow divider [22]. On the other hand in
the carina the shear stress is high and thus the plaque
burden was found to be reduced 10. At the distal rim of
the ostium of the side branch and in particular at the
outer side of the flow divider low or oscillating shear
stress have been detected and these segments appear to
be susceptible to atherosclerosis [23]. Although the
number of the bifurcations studied is limited there was a
difference in the evolution of the plaque in the proximalnd distally to the bioresorbable scaffold (proximal and distal
r corresponds to dense calcium, the red to necrotic core, the light
Figure 5 Changes in type of the plaque type detected at the coronary bifurcations. For each plaque type, the percent of changes is
reported. AIT, adaptive intimal thickening; CaFA, calcified fibroatheroma; CaTCFA, calcified thin-cap fibroatheroma; FA, fibroatheroma; FC,
fibrocalcific plaque; FT, fibrotic plaque; PIT, pathologic intimal thickening; TCFA, thin-cap fibroatheroma.
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burden appeared to be reduced in the proximal bifur-
cation while there were no changes in the distal. The re-
duction of the plaque burden in proximal bifurcation
can be attributed to the treatment with statins [24,25].
Although the small number of the distal bifurcations
studied does not allow us to draw firm conclusions and
potentially detect significant changes between baseline
and follow-up the effect of the downstream drug delivery
from the BVS on vessel wall physiology and on the distal
bifurcation cannot also be excluded. Several studies have
demonstrated that implantation of a drug eluting stent
can affect plaque development [26,27]. Krasouski et al.
demonstrated that patients treated with a drug eluting
were less likely to develop stenoses at the downstream
vessel and events compared to patients receiving bare-
metal stents fact that was attributed to a beneficial effect
of the downstream drug delivery [26]. On the other
hand, Wakabayashi et al. showed that in patients treated
with a paclitaxel eluting stent there is an increase in the
plaque burden up to 15mm distally to the implanted
stent. This has been attributed to the inflammation trig-
gered by the antiproliferative drug [27]. In addition, cu-
mulative evidence suggests that after drug-eluting stent
implantation there is endothelial dysfunction in the dis-
tal vessel due to the eluted drug which can promote
plaque progression [28-30]. Although there is lack of
evidence about the impact of everolimus elution on
endothelial function and on plaque development in thedownstream vessel a reaction of the vessel to the pres-
ence of the drug cannot be excluded. This could poten-
tially promote atherosclerosis and hence counterbalance
the effect of statins.
Study limitations
The most important limitation of this analysis is the
small number of the recruited patients and the limited
number of the bifurcations studied. Hence this report
may be underpowered to detect differences in plaque
burden and composition. Thus this study should be con-
sidered as an exploratory and hypothesis generating ana-
lysis and the results should be interpreted with caution.
In view of the limited data we were restricted either to a
descriptive report or to a simplified statistic analysis and
we did not take into consideration the clustering effect.
Furthermore, in contrast to previous studies serial IVUS
imaging was performed only in the main branch and not
in the side branch of the bifurcation lesion [31]. This is
a significant limitation of our study since we were not
able to evaluate coronary pathology in side branches and
detect changes in plaque composition and burden in
these segments.
Conclusions
This study analyzed serial IVUS-VH data obtained at
baseline and 2 years follow-up from patients with ob-
structive coronary artery disease implanted with a BVS
and treated with statins and demonstrated no significant
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coronary bifurcations located more than 5 mm from the
treated segment. Analyzing separately bifurcations lo-
cated proximally and distally to the BVS we found
plaque regression at the proximal group and no changes
in the plaque at the distal group. This may potentially be
due to the effect of the downstream drug delivery on
vessel wall physiology; however further studies are
required to confirm this finding and examine the conse-
quences of the everolimus elution on the downstream
vessel.
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